Literature DB >> 3982646

Motor function in the normal aging population: treatment with levodopa.

R P Newman, P A LeWitt, M Jaffe, D B Calne, T A Larsen.   

Abstract

In normal elderly humans there is progressive motor dysfunction and loss of nigrostriatal neurons and brain dopamine similar to, although of a milder degree than, that seen in Parkinson's disease. Ten healthy elderly volunteers were given carbidopa/levodopa or placebo in a double-blind crossover study. We measured movement velocity, reaction time, tremor, visual evoked response (VER), and electroretinography (ERG). Significant changes were seen only in ERG. Motor functions and VER were unchanged. Although there appeared to be pharmacologic activity (ie, changes in ERG), levodopa, in adequate antiparkinson dosage, had no impact on the mild extrapyramidal impairment of normal elderly subjects.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3982646     DOI: 10.1212/wnl.35.4.571

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  15 in total

1.  Effects of brain-derived neurotrophic factor on dopaminergic function and motor behavior during aging.

Authors:  H A Boger; P Mannangatti; D J Samuvel; A J Saylor; T S Bender; J F McGinty; A M Fortress; V Zaman; P Huang; L D Middaugh; P K Randall; L D Jayanthi; B Rohrer; K L Helke; A-C Granholm; S Ramamoorthy
Journal:  Genes Brain Behav       Date:  2010-10-19       Impact factor: 3.449

2.  Response of aged parkinsonian monkeys to in vivo gene transfer of GDNF.

Authors:  M E Emborg; J Moirano; J Raschke; V Bondarenko; R Zufferey; S Peng; A D Ebert; V Joers; B Roitberg; J E Holden; J Koprich; J Lipton; J H Kordower; P Aebischer
Journal:  Neurobiol Dis       Date:  2009-08-04       Impact factor: 5.996

3.  Aged monkeys as a partial model for Parkinson's disease.

Authors:  P J Hurley; J D Elsworth; M C Whittaker; R H Roth; D E Redmond
Journal:  Pharmacol Biochem Behav       Date:  2011-05-18       Impact factor: 3.533

4.  Nigral pathology and parkinsonian signs in elders without Parkinson disease.

Authors:  Aron S Buchman; Joshua M Shulman; Sukriti Nag; Sue E Leurgans; Steven E Arnold; Martha C Morris; Julie A Schneider; David A Bennett
Journal:  Ann Neurol       Date:  2012-02       Impact factor: 10.422

5.  Early diagnosis of Parkinson's disease.

Authors:  A M Bakheit
Journal:  Postgrad Med J       Date:  1995-03       Impact factor: 2.401

6.  L-DOPA reverses motor deficits associated with normal aging in mice.

Authors:  Erika Allen; Kirsten M Carlson; Michael J Zigmond; Jane E Cavanaugh
Journal:  Neurosci Lett       Date:  2010-11-25       Impact factor: 3.046

Review 7.  Motor control and aging: links to age-related brain structural, functional, and biochemical effects.

Authors:  Rachael D Seidler; Jessica A Bernard; Taritonye B Burutolu; Brett W Fling; Mark T Gordon; Joseph T Gwin; Youngbin Kwak; David B Lipps
Journal:  Neurosci Biobehav Rev       Date:  2009-10-20       Impact factor: 8.989

8.  Striatal dopamine transporters correlate with simple reaction time in elderly subjects.

Authors:  Christopher H van Dyck; Robert A Avery; Martha G MacAvoy; Kenneth L Marek; Donald M Quinlan; Ronald M Baldwin; John P Seibyl; Robert B Innis; Amy F T Arnsten
Journal:  Neurobiol Aging       Date:  2007-03-23       Impact factor: 4.673

9.  Parkinsonian abnormality of foot strike: a phenomenon of ageing and/or one responsive to levodopa therapy?

Authors:  J R Hughes; S G Bowes; A L Leeman; C J O'Neill; A A Deshmukh; P W Nicholson; S M Dobbs; R J Dobbs
Journal:  Br J Clin Pharmacol       Date:  1990-02       Impact factor: 4.335

10.  Age influences magnitude but not duration of response to levodopa.

Authors:  R Durso; K Isaac; L Perry; M Saint-Hilaire; R G Feldman
Journal:  J Neurol Neurosurg Psychiatry       Date:  1993-01       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.